Clinical Trial

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer

Study acronym: ENZAMET
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine the effectiveness of enzalutamide, versus a conventional non-steroidal anti androgen (NSAA), when combined with a luteinizing hormone releasing hormone analog (LHRHA) or surgical castration, as first line androgen deprivation therapy (ADT) for newly diagnosed metastatic prostate cancer.
Protocol Amendment History 15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2015-05-13; most recent amendment 2025-02-03.
Status change: Recruiting → Active, Not Recruiting 2017-03-26
Trial Details
NCT Number NCT02446405
Lead Sponsor University of Sydney
Collaborators: Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Cancer Trials Ireland, Canadian Cancer Trials Group, Astellas Pharma Inc
Conditions Prostatic Neoplasms
Enrollment 1,125 participants
Start Date 2014-03
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-02-06